@CarolineDiorio @ChildrensPhila @RheumNow Indeed, there are a lot of familiar HLH/MAS friends in the post-CAR-T CRS mix... (indeed, rheum friends from many places) @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/OzWu3MV1FA

• https://x.com/drdavidliew/status/1983704194902323303/photo/1
• https://x.com/drdavidliew/status/1983704194902323303/photo/1

Another toxicity signal to watch in the CAR T space: LICATs Abstract 1537 reports a new immune-related toxicity distinct from CRS or ICANS: 🔹Affects organs prev involved in autoimmune dx: skin (35%) and kidneys (22%) 🔹Mostly mild (Grade 1–2); 3 cases Grade 3 @RheumNow #ACR25 https://t.co/mtZh47nWtv

• https://x.com/AkhilSoodMD/status/1983703327906132314/photo/1

I've always (very) simplistically considered post-CAR-T CRS and HLH/MAS in the same bucket, and there certainly are substantial similarities. It raises the obvious question - can we borrow therapies? @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/2HkHxpl89u

• https://x.com/drdavidliew/status/1983703327323123767/photo/1

What dictates how severe CRS is following CAR-T? (Often the critical question, and will especially be in the autoimmune space, where CAR-T is largely less time-critical) @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/u0w4lx7YVn

• https://x.com/drdavidliew/status/1983702263207227461/photo/1
• https://x.com/drdavidliew/status/1983702263207227461/photo/1

@CarolineDiorio @ChildrensPhila eloquently told the #ACR25 BCRC pre-meeting about the lessons they've learned about CRS and ICANS, the major CAR-T toxicities. Many questions still to answer, but they've also understood a lot we can learn from. @RheumNow https://t.co/Jhk1eCLpD4

• https://x.com/drdavidliew/status/1983701167944429634/photo/1
• https://x.com/drdavidliew/status/1983701167944429634/photo/1

CAR-T vs bispecific antibodies - what's the difference? @andrew02114 @MGHCancerCenter with the heme-onc point of view in the #ACR25 BCRC @RheumNow https://t.co/7KJCfiQKWM

• https://x.com/drdavidliew/status/1983698141934449115/photo/1
• https://x.com/drdavidliew/status/1983698141934449115/photo/1
• https://x.com/drdavidliew/status/1983698141934449115/photo/1

CAR-T toxicity in hematology (the things we have to look out for in rheumatology, as application of CAR-T potentially broadens) @andrew02114 @MGHCancerCenter with the heme-onc point of view in the #ACR25 BCRC @RheumNow https://t.co/1YjadL7LCF

• https://x.com/drdavidliew/status/1983697961533276665/photo/1
• https://x.com/drdavidliew/status/1983697961533276665/photo/1
• https://x.com/drdavidliew/status/1983697961533276665/photo/1

Andrew Yee @andrew02114 of @MGHCancerCenter details out how quickly the CAR-T paradigm changed in myeloma/lymphoma - from newsworthy to routine. Now that much more about CAR-T has been worked out, will adoption be quicker in autoimmune disease? #ACR25 BCRC pre-meeting @RheumNow https://t.co/oNuPXCwWQ9

• https://x.com/drdavidliew/status/1983696202484068592/photo/1
• https://x.com/drdavidliew/status/1983696202484068592/photo/1
• https://x.com/drdavidliew/status/1983696202484068592/photo/1

What to use in future for active #Sjogren's #SjD B cell depletion, signal attenuation Ianalumab 2+ phase3 RCTs Telitacept +RCT Nipocalimab FcRn +Ph2 Dazodalibep CD40L +Ph2 +RCTs HCQ+Lef Rituximab ?BTKi #ACR25 @ACRheum @RheumNow abst#LB24, LB11

Post-CAR-T myelopathy has been an issue in heme onc, and is still an unpredictable quantity without a clear cause. Will this be a problem for autoimmune CAR-T as we gain more experience? @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/RhhdOiyEAX

• https://x.com/drdavidliew/status/1983734589400203526/photo/1
• https://x.com/drdavidliew/status/1983734589400203526/photo/1
• https://x.com/drdavidliew/status/1983734589400203526/photo/1

CAR-T Cell Therapies Show Promise for Autoimmune Disease Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc

Phase 1 study of CAR-Treg in difficult to treat RA 4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required & good prelim safety data CAR-T remains exciting, but less of the "totally magical everyone cured" stuff we saw w/initial CAR-T reports @RheumNow #ACR25 https://t.co/kjBIkLCYpF

• https://x.com/EBRheum/status/1983643165383889329/photo/1
• https://x.com/EBRheum/status/1983643165383889329/photo/1
• https://x.com/EBRheum/status/1983643165383889329/photo/1
• https://x.com/EBRheum/status/1983643165383889329/photo/1

Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis? Early data n=6 treated w low dose (3 per arm), ongoing and doses will escalate Improvemt in #clinical #disease #activity less inflammation on #synovial #biopsies 3 pts #LB23 #ACR25 @RheumNow @ACRheum https://t.co/PkhsvztVjx

• https://x.com/Janetbirdope/status/1983600216126431595/photo/1

#ACR25 Abstr#2695 Inguinal lymph node biopsies pre- and post-OBI, RTX, BLIN & CD19 CAR-T showed complete tissue depletion with CAR-T. B-cells reduced but often incomplete with protein-based depleters; OBI being the best. Still don’t agree with “immune reset” @RheumNow #ACRBest https://t.co/Sq7m9sXlLP

• https://x.com/Yuz6Yusof/status/1983587064802316679/photo/1
• https://x.com/Yuz6Yusof/status/1983587064802316679/photo/1